Sofia

• A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer Ended recruitment
  2024-511038-11-00 4 2024-09-24 advanced prostate cancer
• A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in … Ended recruitment
  2023-506769-67-00 4 2024-09-04 Moderate to Severely Active Ulcerative Colitis
• A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infu … Ended recruitment
  2024-510965-41-00 5 2024-09-03 Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
• MLS-101-901: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hyper … Ended recruitment
  2023-508670-28-00 5 2024-08-26 Hypertension
• ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended recruitment
  2023-506876-28-00 5 2024-08-01 The medical condition we are investigating is type 1 AMI (STEMI and NS
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High- … Ended recruitment
  2023-510178-15-00 5 2024-07-31 High-risk Large B-cell Lymphoma
• A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) Ended recruitment
  2024-512747-23-00 5 2024-07-30 Transfusion-Dependent Alpha- or Beta-Thalassemia
• A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 versus Placebo in Participants wit … Ended recruitment
  2023-506335-15-00 5 2024-07-18 Major Depressive Disorder
• ACP-204 in Adults with Alzheimer’s Disease Psychosis Ended recruitment
  2023-507325-42-00 4 2024-07-02 Alzheimer Disease psychosis
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants with Severe Alopecia Areata Ended recruitment
  2023-505061-82-01 5 2024-06-17 Alopecia Areata
• A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended recruitment
  2023-505435-12-00 5 2024-06-04 Asthma
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i … Ended recruitment
  2023-506906-38-00 5 2024-05-23 Follicular Lymphoma
• A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended recruitment
  2023-508085-15-00 5 2024-05-15 Chronic Obstructive Pulmonary Disease
• A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o … Ended recruitment
  2022-502518-98-00 5 2024-04-26 nonsegmental vitiligo
• A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLV … Ended recruitment
  2023-507456-69-00 4 2024-04-25 Atopic Dermatitis
• Randomised, placebo-controlled Phase II proof of concept study of efficacy and safety of a novel rifamycin SV in situ gelling rectal solutio … Ended recruitment
  2023-506917-23-00 4 2024-04-19 patients with mild to moderate left-sided ulcerative colitis
• Selective Treatment of Oral Povorcitinib in Vitiligo Study 2 (STOP-V2) Ended recruitment
  2023-506011-18-00 5 2024-04-17 Vitiligo
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit … Ended recruitment
  2023-505928-59-00 5 2024-04-15 Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
• A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo. Ended recruitment
  2023-506195-27-00 5 2024-04-05 non-segmental vitiligo
• INSPIRE (INcreased Sun exposure without Pain In Research subjects with EPP). Ended recruitment
  2023-506735-15-00 5 2024-04-05 Erythropoietic Protoporphyria or X-Linked Protoporphyria
• A Phase III Study to assess efficacy, safety, and tolerability of Zibotentan combined with Dapagliflozin, compared to Dapagliflozin, in pati … Ended recruitment
  2023-504124-26-00 5 2024-04-04 Chronic Kidney Disease and High Proteinuria
• ATHENA: A research study looking into how ziltivekimab works compared to placebo in people with heart failure and inflammation Ended recruitment
  2023-506988-34-00 5 2024-03-27 Heart failure with mildly reduced or preserved ejection fraction and s
• 52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co … Ended recruitment
  2022-502161-19-00 5 2024-03-12 Chronic Spontaneous Urticaria
• A study of zipalertinib and chemotherapy compared with chemotherapy alone in patients with advanced Non-Small Cell Lung Cancer with Epiderma … Ended recruitment
  2023-503575-21-00 5 2024-01-23 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Showing 289–312 of 590 trials